Skip to Content
Merck
CN

Spotlight on adapalene in acne vulgaris.

American journal of clinical dermatology (2004-11-24)
John Waugh, Stuart Noble, Lesley J Scott
ABSTRACT

Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris. In clinical trials, 0.1% adapalene gel has proved to be effective in this indication and was as effective as 0.025% tretinoin gel, 0.1% tretinoin microsphere gel, 0.05% tretinoin cream and 0.1% tazarotene gel once every two days; however, the drug was less effective than once-daily 0.1% tazarotene gel. It can be used alone in mild acne or in combination with antimicrobials in inflammatory acne and has proved efficacious as maintenance treatment. Adapalene has a rapid onset of action and a particularly favorable tolerability profile compared with other retinoids. These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris.

MATERIALS
Product Number
Brand
Product Description

USP
Adapalene, United States Pharmacopeia (USP) Reference Standard
Adapalene for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Adapalene, Pharmaceutical Secondary Standard; Certified Reference Material
Adapalene, European Pharmacopoeia (EP) Reference Standard